DCIS
Tool Uses Clinicopathologic, Genomic Features to Predict Chemo Benefit in Early Breast Cancer
A new validated clinical tool that integrates clinicopathologic and genomic features can guide adjuvant ...
JUNE 11, 2021
DCIS Biological Risk Signature Predicts Recurrence, Radiation Benefit
Women with ductal carcinoma in situ and elevated commercial DCISion scores had a significantly higher risk for ...
MAY 3, 2021
Women Willing to Accept Some Risks of DCIS to Avoid Invasive Therapy
Orlando, Fla.—While some patients are unwilling to accept any degree of breast cancer risk as a trade-off for ...
JANUARY 21, 2019
Contralateral Risk For DCIS Patients Low
Las Vegas—The rate of contralateral prophylactic mastectomy in women with ductal carcinoma in situ more than ...
JUNE 21, 2017
When Does DCIS Require Post-op Radiation Therapy?
How should oncologists gauge whether to send patients for radiation therapy after breast-conserving surgery for ...
MARCH 27, 2017
DCIS Risk Biomarker on the Horizon
Researchers have completed the first of three planned validation studies for PreludeDx. The tool is designed to ...
MARCH 15, 2017
Value of ER/PR Tests on DCIS Core Biopsies Questioned
Results from automatic estrogen receptor (ER) and progesterone receptor (PR) tests on breast core needle biopsies ...
OCTOBER 18, 2016
Data Show Risk of Watch-and-Wait Approach to DCIS
In the past couple of years, the risk of overtreating patients with ductal carcinoma in situ (DCIS) with surgery ...
SEPTEMBER 1, 2016
Ipsilateral Breast Ca More Common With Delayed RT for DCIS
New Orleans—A delay in the initiation of radiation therapy of more than eight weeks after breast-conserving ...
JULY 18, 2016
Better Prognostic Tools Are Needed for DCIS
In recent years, controversy has swirled around the treatment of ductal carcinoma in situ (DCIS). At the 2015 San ...
APRIL 11, 2016
